

10-18-05  
EXPRESS MAIL ED 29275461005  
B/1652  
PRO/8B/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/086,913
Filing Date	March 1, 2002
First Named Inventor	Higuchi, et al.
Art Unit	1652
Examiner Name	Maryann Monshipouri
Attorney Docket Number	068528.0103

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement  <input checked="" type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<div>Remarks</div>		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Baker Botts LLP	Customer No.	21003
Signature			
Printed name	Lisa B. Kole		
Date	10/17/2005	Reg. No.	35,225

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	(Express mail)		
Typed or printed name	Lisa B. Kole	Date	10/17/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Higuchi et al. Examiner: Maryam Monshipouri  
Serial No. : 10/086,913 Group Art Unit: 1652  
Filed : March 1, 2002  
For : PREVENTION AND TREATMENT OF MYCOPLASMA-  
ASSOCIATED DISEASES  
Customer No. : 21003

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**EXPRESS MAIL NO. ED 292754610US**

Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, Applicants respectfully request that the documents listed below and on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application. Copies of the listed documents are enclosed.

71. Kaji M et al., 2005, "A side effect of neuraminidase inhibitor in a patient with liver cirrhosis," J. Infect. Chemother. 11:41-43.

72. Amaya MF et al., 2004, "Structural insights into the catalytic mechanism of *Trypanosoma cruzi* trans-sialidase," Structure 12:775-784.

73. Higuchi ML et al., 2004, "*Trypanosoma cruzi* trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia," Medical Hypothesis 63:616-623.

74. Higuchi ML et al., 2003, "Coinfection with *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in ruptured plaques associated with acute myocardial infarction," Arq. Bras. Cardiol. 81(1):12-22.
75. Higuchi ML et al., 2003, "Pathophysiology of the heart in Chagas' disease: current status and new developments," Cardiovasc. Res. 60: 96- 107.
76. Watts AG et al., 2003, "*Trypanosoma cruzi* trans-sialidase operates through a covalent sialyl-enzyme intermediate:tyrosine is the catalytic nucleophile," J. Am. Chem. Soc. 9(25): 7532-7533.
77. Aiello VD et al., 2002, "A possible role for complement in the pathogenesis of chronic chagastic cardiomyopathy," J. Pathol. 197:224-229.
78. Buschiazzi et al., 2002, "The crystal structure and mode of action of trans-sialidase, a key enzyme in *Trypanosoma cruzi* pathogenesis," Molecular Cell 10:757-768.
79. Dallo SF et al., 2000, "Intracellular DNA replication and long-term survival of pathogenic mycoplasmas," Microb. Pathog 29:301-309.
80. Palomino AS et al., 2000, "Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and *Trypanosoma cruzi* antigens," Ann. Trop. Med. Parasitol. 94(6):571-579.
81. Treanor JJ et al., 2000, "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. U.S. oral neuraminidase study group," JAMA 283(8):1016-1024.
82. Monto AS et al., 1999, "Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenza A and B virus infections." J. Infect. Dis. 180: 254-261.

83. Higuchi ML et al., 1997, "Association of an increase in CD8+ T cells with the presence of *Trypanosoma cruzi* antigens in chronic, human chagasic myocarditis," Am. J. Trop. Med. Hyg. 56:485-489.

84. Higuchi ML et al., 1987, "The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies," Clin. Cardiol. 10:665-670.


85. Libby P et al., 1986, "A neuraminidase from *Trypanosoma cruzi* removes sialic acid from the surface of myocardial and endothelial cells, " J. Clin. Invest. 77:127-135.

86. Soleslavsky O. et al., 1968, "Adsorption of *Mycoplasma pneumoniae* to neuraminic acid receptors of various cells and possible role in virulence." J. Bacteriol. 96(3):695-705.

Citation of these references is not an admission that any one is prior art against the present invention.

Please charge the fee due for this submission to Deposit Account No. 02-4377. A copy of this paper is enclosed.

Respectfully submitted,  
BAKER/BOTTS L.L.P.

A handwritten signature in black ink, appearing to read 'LBK', is written over a horizontal line.

Lisa B. Kole

PTO Reg. No. 35,225

212-408-2628

<b>Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. 068528.0103	Serial No. 10/086,913
	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652
	Examiner: Maryann Monshipouri	

### U.S. PATENT DOCUMENTS

*Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

### FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
		"A Side effect of neuraminidase inhibitor in a patient with liver cirrhosis" by Kaji, et al. <u>J. Infect. Chemother.</u> (2005)(11:41-43)
		"Structural Insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase" by Amaya, et al., <u>Structure</u> , Vol. 12, pp. 775-784, May 2004
		"Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia" by Higuchi, <u>Medical Hypotheses</u> (2004)(63, 616-623).

NY02:531905.1
Examiner _____ Date Considered _____

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 068528.0103	Serial No. 10/086,913
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652
	Examiner: Maryann Monshipouri	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
		"Coinfection with mycoplasma pneumoniae and chlamydia pneumoniae in ruptured plaques associated with acute myocardia infarction" by Higuchi, et al., Arq. Bras Cardiol, Vol. 81, No. 1, 12-22, 2003.
		"Pathophysiology of the heart in chagas' disease: current status and new developments" by Higuchi, et al., 2003 European Society of Cardiology, pp. 96-107
		"Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: Tryosine is the catalytic nucleophile" by Watts, et al., J. Am. Chem. Soc. 2003, 125, 7532-7533.
		A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy" by Aiello, et al., Journal of Pathology, 2002, 197; 224-229
		The Crystal Structure and Mode of Action of Trans-sialidase, a key enzyme in trypanosoma cruzi pathogenesis by Buschiazzi, et al., Molecular Cell, Vol. 10, 757-758, Oct. 2002
		Intracellular DNA replication and long term survival of pathogenic mycoplasmas" by Dallo, et al., Microbial Pathogenesis, 2000, 29: 301-309
		Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens" by Palomino, et al., Annals of Tropical Medicine and Parasitology, Vol. 94, No. 6, 571-579 (2000).
		Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza by Treanor, et al., JAMA, Feb. 23, 2000, Vol. 283
		Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the treatment of Influenza A and B Virus Infections by Monto, et al., Journal of Infectious Diseases, 1999: 180; 254-61.
		Association of an increase in CD8+ T cells with the presence of trypanosoma cruzi antigens in chronic human chagasic mycoarditis by Higuchi, et al., Am. J.Trop. Med. Hyg., 56(5), 1997, pp. 485-489

NY02:531905.1

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\_\_\_\_\_

--	--	--	--

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.